The insulin-like growth factor system in kidney disease and hypertension

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 1, 2012, Pages 86-91

  Bach, Leon A ^a,b  

^a Department of Endocrinology and Diabetes ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

diabetic nephropathy; growth hormone; hypertension; insulin like growth factor

Indexed keywords

GROWTH HORMONE RECEPTOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C;

APOPTOSIS; DIABETIC NEPHROPATHY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INSULIN RESISTANCE; KIDNEY DEVELOPMENT; KIDNEY DISEASE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENOVASCULAR HYPERTENSION; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 83055164470     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834dc1a2     Document Type: Review

References (33)

1. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007; 6:821-833. (Pubitemid 47500506)
2. Frasca F, Pandini C, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19:3278-3288. (Pubitemid 29193789)
3. Souza RF, Wang SN, Thakar M, et al. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 1999; 18:4063-4068. (Pubitemid 29363913)
4. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23:824-854. (Pubitemid 35454590)
5. Bach LA, Headey SJ, Norton RS. IGF-binding proteins: the pieces are failing into place. Trends Endocrinol Metab 2005; 16:228-234. (Pubitemid 40853886)
6. Rabkin R, Schaefer F. New concepts: growth hormone, insulin-like growth factor-I and the kidney. Growth Horm IGF Res 2004; 14:270-276. (Pubitemid 38878052)
7. Kumar PA, Brosius FC 3rd, Menon RK. The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy. Curr Diab Rev 2011; 7:50-55.
8. Lupu F, Terwilliger JD, Lee K, et al. Roles of growth hormone and insulinlike growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229:141-162. (Pubitemid 32061720)
9. Moerth C, Schneider MR, Renner-Mueller I, et al. Postnatally elevated levels of insulin-like growth factor (IGF)-II fail to rescue the dwarfism of IGF-I-deficient mice except kidney weight. Endocrinology 2007; 148:441-451. (Pubitemid 46021476)
10. Sjogren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999; 96:7088-7092. (Pubitemid 29275014)
11. Nordstrom SM, Tran JL, Sos BC, et al. Liver-derived IGF-I contributes to GH-dependent increases in lean mass and bone mineral density in mice with comparable levels of circulating GH. Mol Endocrinol 2011; 25:1223-1230.
12. Nagasu H, Satoh M, Kuwabara A, et al. Overexpression of klotho protein modulates uninephrectomy-induced compensatory renal hypertrophy by suppressing IGF-I signals. Biochem Biophys Res Commun 2011; 407: 39-43.
13. Levin-Iaina N, Iaina A, Raz I. The emerging role of NO and IGF-1 in early renal hypertrophy in STZ-induced diabetic rats. Diabetes Metab Res Rev 2011; 27:235-243.
14. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008; 74:22-36. (Pubitemid 351841893)
15. Fujinaka H, Katsuyama K, Yamamoto K, et al. Expression and localization of insulin-like growth factor binding proteins in normal and proteinuric kidney glomeruli. Nephrology 2010; 15:700-709.
16. Kumar PA, Kotlyarevska K, Dejkhmaron P, et al. Growth hormone (GH)-dependent expression of a natural antisense transcript induces zinc finger E-box-binding homeobox 2 (ZEB2) in the glomerular podocyte: a novel action of GH with implications for the pathogenesis of diabetic nephropathy. J Biol Chem 2010; 285:31148-31156.
17. Yoo EG, Lee WJ, Kim JH, et al. Insulin-like growth factor-binding protein-3 mediates high glucose-induced apoptosis by increasing oxidative stress in proximal tubular epithelial cells. Endocrinology 2011; 152:3135-3142.
18. Peters I, Tossidou I, Achenbach J, et al. IGF-binding protein-3 modulates TGFbeta/BMP-signaling in glomerular podocytes. J Am Soc Nephrol 2006; 17:1644-1656. (Pubitemid 43794667)
19. Worthmann K, Peters I, Kumpers P, et al. Urinary excretion of IGFBP-1 and-3 correlates with disease activity and differentiates focal segmental glomerulosclerosis and minimal change disease. Growth Factors 2010; 28:129-138.
20. Tokunaga K, Uto H, Takami Y, et al. Insulin-like growth factor binding protein-1 levels are increased in patients with IgA nephropathy. Biochem Biophys Res Commun 2010; 399:144-149.
21. Lepenies J,WuZ, Stewart PM, et al. IGF-1, IGFBP-3 and ALS in adult patients with chronic kidney disease. Growth Horm IGF Res 2010; 20:93-100.
22. Feldt-Rasmussen B, El Nahas M. Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease. Semin Nephrol 2009; 29:50-58.
23. Guebre-Egziabher F, Juillard L, Boirie Y, et al. Short-term administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis. J Clin Endocrinol Metab 2009; 94:2299-2305.
24. Conti E, Carrozza C, Capoluongo E, et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004; 110:2260-2265. (Pubitemid 39372511)
25. Ezzat VA, Duncan ER, Wheatcroft SB, Kearney MT. The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obesity Metab 2008; 10:198-211. (Pubitemid 351247336)
26. Yang AL, Yeh CK, Su CT, et al. Aerobic exercise acutely improves insulin-and insulin-like growth factor-1-mediated vasorelaxation in hypertensive rats. Exp Physiol 2010; 95:622-629.
27. Schutte AE, Huisman HW, van Rooyen JM, et al. A significant decline in IGF-I may predispose young Africans to subsequent cardiometabolic vulnerability. J Clin Endocrinol Metab 2010; 95:2503-2507.
28. Perticone F, Maio R, Sciacqua A, et al. Insulin-like growth factor-1 and glomerular filtration rate in hypertensive patients. J Hypertens 2009; 27:613-617.
29. Telgmann R, Dordelmann C, Brand E, et al. Molecular genetic analysis of a human insulin-like growth factor 1 promoter P1 variation. FASEB J 2009; 23:1303-1313.
30. Faienza MF, Santoro N, Lauciello R, et al. IGF2 gene variants and risk of hypertension in obese children and adolescents. Pediatr Res 2010; 67:340-344.
31. Sookoian S, Gianotti TF, Gemma C, et al. Role of genetic variation in insulinlike growth factor 1 receptor on insulin resistance and arterial hypertension. J Hypertens 2010; 28:1194-1202.
32. Horio T, Kamide K, Takiuchi S, et al. Association of insulin-like growth factor-1 receptor gene polymorphisms with left ventricular mass and geometry in essential hypertension. J Hum Hypertens 2010; 24:320-326.
33. Friedrich N, Aumann N, Dorr M, et al. Lack of association between insulin-like growth factor-1 or insulin-like growth factor-binding protein-3 and left ventricular hypertrophy: results of the Study of Health in Pomerania. J Hypertens 2010; 28:856-864.